• Forbes reports that “sustainability is increasingly becoming a necessity for corporations due to changing perspectives around the world”
• Unfortunately, while 90% of executives think sustainability is important, only 60% of companies have a sustainability strategy
• ACP’s sustainable operating practices appear ideally aligned with today’s expectations

With a focus on sustainability becoming increasingly essential for companies to succeed in today’s market, American Cannabis Partners (“ACP”) has made its sustainable operating practices a top priority. The company is “contending for first place in the U.S. cannabis industry through proven strategies that continue to accelerate ACP in assets, operations, expansions and market share” (https://acpfarms.com). “Sustainability is increasingly becoming a necessity for corporations due to changing perspectives around the world,” reports Forbes in an article titled “Why Corporate Strategies Should Be Focused on Sustainability.” The article noted that “it is becoming even more critical for companies to address the gap between knowing and doing by embracing sustainable business practices. Sustainability can be defined as providing for the present needs without compromising the needs of the future generations to meet theirs. It has three pillars: economic, environmental and social.” Forbes reported that, while 90% of executives think sustainability is important, only 60% of companies have a sustainability strategy. “Often, companies that speak of being sustainable are lacking when it comes to implementation,” the article noted. “Economic, social and environmental sustainability is a must in today’s business environment. It has a lot of benefits as well. The article pointed out several key reasons why organizations should implement sustainability strategies, including adding brand value and a competitive advantage, meeting consumer demand, increasing efficiency, attracting talent and creating new opportunities. With that in mind, ACP’s sustainable operating practices (https://ibn.fm/8kvxU) appear ideally aligned with today’s expectations. The company is “committed to operating business in a manner that has a positive impact on the environment, employee, and customer experience,” with an organic cultivation model that includes “the implementation of sustainable operating practices that reduce the company’s environmental footprint and increase its social responsibility. A comprehensive approach is taken to maximize impacts on our operations. Use of local purchasing and employment, environment-friendly products, energy and water conservation efforts, and a waste management program have increased our ‘triple bottom line,’ positively impacting people, planet, and profit.” American Cannabis Partners is focused on three business segments: real estate, acquisition and development of proprietary assets, and ongoing cultivation operations. Led by a seasoned management team with more than three decades of canna-business experience, ACP is guided by its strategy to capture opportunities in real estate and licensing in states that have recently passed cannabis-legalization legislation, thereby equipping the company to capitalize on federal interstate-commerce opportunities. For more information, visit the company’s website at www.ACPFarms.com. NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://ibn.fm/ACP

• FingerMotion is an Nasdaq-traded company making inroads among China’s huge tech-hungry population with mobile services and big data analytics for commercial operations
• FingerMotion recently announced upgrades to its Sapientus division, which is currently focused on providing the insurance industry with consumer analytics in an economy that is still developing standards far or evaluating risk ratings
• Amid the upgrades, Sapientus also secured a renewed agreement with global reinsurance company Pacific Life Re to provide risk-rating capabilities in China
• Much of FingerMotion’s success has been built on its successful partnering with telecommunications giants China Unicom and China Mobile

An increasing number of companies and customers are moving toward interactive chats and artificial intelligence use for securing products and services, leading service providers in turn to analyze their tools for marketing and operational success and to focus on their business messaging platforms (https://ibn.fm/s7qSh). While industries still talk about managing “digital transformations” of their legacy strategies, much of the world appears to have arrived at a “post-digital” plateau in which online technology is not so much noteworthy but expected as a means for facilitating interactions between companies and customers. “Our research has shown that companies evolving to future-ready systems are growing at twice the rate of companies that are unable to scale innovation,” global professional services company Accenture’s managing director and insurance practice lead for Southeast Asia told Insurance Business magazine recently. “Companies would do well to channel their investments toward emerging and flexible technologies, such as AI and analytics, microservices, and cloud solutions,” the director, Elysia Chan, said. “Such technology enables innovation and new ways of working such as Agile and DevSecOps practices that can serve to catalyse the realisation of business value for insurance companies.” Mobile technology services provider FingerMotion (NASDAQ: FNGR) is carving out its own place in communications technology services in Asia, developing operational partnerships with telecommunications giants China Unicom and China Mobile to reach a wide base of mobile users in that country and then building on it with a diversity of service products. FingerMotion’s offerings have largely focused on phone top-up and SMS messaging services in the nation that claims about one-fifth of the world’s total population and more than 450 million 5G mobile phone users currently. However, U.S.-based FingerMotion has also used its in-country collaborations to develop a mobile device protection business it expects to build revenues nationwide (https://ibn.fm/6ZDS1) and a big data arm called Sapientus that gained attention when global reinsurance company Pacific Life Re contracted with FingerMotion (and then renewed the agreement) to provide risk-rating capabilities for China’s developing insurance industry (https://ibn.fm/1k8Qj). FingerMotion’s announcement Aug. 24 that it had updated is Sapientus division algorithms with “more elaborative auxiliary data” for a better analytical engine and the rollout of its API for commercial risk-rating services indicated the company’s commitment to building a strong revenue stream in China’s big data economy. “Our risk rating API platform is the foundational end product built upon collaborative research conducted with our core partners over the course of the past year,” FingerMotion CEO Martin Shen stated in conjunction with the announcement. “We look forward to leveraging this significant achievement.” For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• Freight Technologies is an emerging growth company whose unique solutions suite is designed to optimize and automate the supply chain process and provide a platform for B2B cross-border shipping in North America
• The company recently filed Form F-1 with the SEC registering more than 19 million ordinary shares for resale by selling shareholders identified in the registration statement
• CEO Javier Selgas hailed the milestone as a move that positions the company to continue to work with the capital markets to foster company growth
• The filing comes amid favorable market reports that evidence resurgence of the truck freight market in North America

Emerging growth company Freight Technologies (NASDAQ: FRGT), often abbreviated as Fr8Tech, recently filed a Form F-1 with the Securities and Exchange Commission (“SEC”) in compliance with the Securities Exchange Act of 1933. A registration statement form, the F-1 is filed by companies incorporated in other jurisdictions (non-US companies) to register additional or existing securities for sale to the investing public. The filing is intended to provide investors with essential data such as a prospectus summary, planned use of proceeds from the sale of the securities, risk factors, financial data, management, and business overview, just to mention a few (https://ibn.fm/ieXOx). In the recently filed Form F-1, Fr8Tech, a British Virgin Islands-incorporated technology company developing supply chain optimization and automation solutions and providing its Fr8App platform for B2B cross-border shipping, registered more than 19 million ordinary shares for resale by selling shareholders identified in the form. “All of the ordinary shares, when sold, will be sold by these selling shareholders. The selling shareholders may sell their ordinary shares from time to time at prevailing market prices. We will not receive any proceeds from the sale of the ordinary shares by the selling shareholders or from the conversion of the preferred shares into ordinary shares,” an excerpt from the amended Form F-1 reads (https://ibn.fm/Kutao). “We are incredibly proud of our team, and thank them for their work and dedication to deliver our F-1 registration, which positions us to be able to continue to grow as a public company. Delivering our registration statement puts us in a position to continue to work with the capital markets to foster the growth of our company,” Fr8Tech CEO Javier Selgas commented (https://ibn.fm/BXtOi). The efforts to grow the company are timely considering the prevailing trends in the North American freight transportation market. According to Statista, the U.S. trucking industry generated $732.3 billion in revenue in 2020 (https://ibn.fm/ehAME), contributing $168.32 billion to the U.S. GDP (https://ibn.fm/PXAjf). And although the sector was affected by the COVID-19 pandemic, as evidenced by the fact that the 2020 figures were a drop from 2019 numbers, the industry is still expected to maintain an annualized market size growth rate of 2.7% between 2017 and 2022 (https://ibn.fm/oaKVO). In Mexico, the road freight market, valued at $81.99 billion in 2021, is expected to reach a valuation of $131.61 billion by 2027, representing a 9.91% CAGR (https://ibn.fm/ScFvB). At the same time, data from the U.S. Bureau of Transportation Statistics show that the cross-border North American truck freight market grew to $827.9 billion in 2021 (https://ibn.fm/S9BRa) from $772 billion in 2020 and $695 billion in 2019 (https://ibn.fm/05FRH). Fr8Tech, which is snugly positioned to benefit from this growth, expects the market to continue growing at rates at least equal to the historical values, according to the recent filing. Through Fr8App, a B2B marketplace powered by artificial intelligence (“AI”) and machine learning (“ML”), Fr8Tech simplifies cross-border shipping and daily carrier operations. The Fr8App offers one of the foremost connected and intelligent freight platforms for cross-border shipping in the North American Free Trade Agreement (“NAFTA”) region. At its core, Fr8Tech is guided by the goal to modernize logistic operations by leveraging technology infrastructure that not only enhances efficiency and experiences for their shippers and carriers but also combines everything in a single control center, optimizes logistics, makes fleets more efficient, and reduces transportation costs. For more information, visit the company’s website at www.Fr8Technologies.com. NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT Corporate Communications IBN (InvestorBrandNetwork) Los Angeles, California www.InvestorBrandNetwork.com 310.299.1717 Office Editor@InvestorBrandNetwork.com

• Evidence suggests that current ADAS solutions relying on cameras for perception are not yet safe enough due to camera’s limited capabilities of providing accurate perception data 24/7
• In a recent article authored for Forbes, Cepton’s co-founder and CEO Jun Pei calls for widespread adoption of sensor suites that include complementary technologies–including lidar, camera, and radar–that seamlessly work together to enhance safety for drivers
• Cepton remains committed to deploying lidar in all vehicles with the goal of making the driving experience safer and more efficient for all road participants; expands collaboration with Koito to extend beyond its current OEM series production program

“If consumers fail to understand the current capabilities of automated systems and demand the right combination of technology in the vehicles, they may be risking their own lives,” said Jun Pei, the co-founder and CEO of Cepton (NASDAQ: CPTN), a world-leading lidar provider, in a recent article he authored for Forbes (https://ibn.fm/PHdDX). Highlighting that the debate over the single most effective sensor technology for ADAS may be pointed in the wrong direction, Pei reflected on his confidence that lidar could be an optimal response to the safety needs of drivers, in addition to enabling autonomous driving capabilities. “Instead of arguing over the best single technology, we need to focus on making different technologies seamlessly work together without disrupting the modern car design and cost structure. With complementing technology and redundancy, our cars can more accurately perceive their environment, thus lowering the risk of accidents,” he said. Tests from the American Automobile Association (“AAA”) revealed that vehicles deploying today’s current ADAS technologies fail to consistently avoid crashes (https://ibn.fm/554uy). It has been known for years that relying on cameras, radars, and software cannot provide enough reliability when it comes to detecting object perception. Even when supported by software and AI, which can extract more useful information from camera data, cameras still face challenges in collecting reliable data. Cameras are not only limited by their 2D nature but are also highly reliant on lighting conditions, which can decrease the quality of data they gather. At the same time, consumers may not fully understand the state of autonomous driving yet and may think the existing technology is more advanced than it is. Therefore, Dr. Pei believes we need to prepare consumers for the arrival of autonomous vehicles with a stronger trust in assisted and autonomous driving technologies. “Several lidar companies—including Luminar, Innoviz and Cepton—have been working with OEMs to deploy lidar in passenger cars in the years ahead.” He notes that those with the most at stake financially—the automakers—already recognize the need for enhancing current safety equipment beyond camera technology. As a result, automakers seeking to develop a more diverse and robust sensor safety suite are increasingly adding lidar. For example, Doug Parks, General Motors’s Vice President for Global Product Development, Purchasing and Supply Chain, pointed out earlier this year at an investor conference that cars without one of the three key technologies—camera, radar, and lidar—will not be able to meet the performance and safety standards customers expect and deserve. Furthermore, Cepton remains committed to making this potentially game-changing technology available in everyday cars, not just luxury vehicles. The Company expects lidar to benefit more consumers as the technology gets rolled out to all cars, making autonomous driving safer for all. Cepton’s partnership with world-leading automotive Tier 1 supplier, Koito, a Tokyo-based manufacturer with century-long operations, marks a significant milestone on Cepton’s journey to lidar commercialization. “We’re working with top 10 global OEMs here in North America and Japan and their strategies are still very much intact. So, the progress has been really good with the top 10 OEMs, and specifically with GM” stated Pei (https://ibn.fm/lGdvZ). Here, Cepton appears to have a competitive advantage. What makes it distinctive from other lidar makers is that on top of performance and automotive-grade reliability, its lidars have a small form factor and low power consumption, which can be easily integrated in various locations within both traditional and electric vehicles (https://ibn.fm/zckr6). For more information, visit the company’s website at www.Cepton.com. NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN

• Lexaria Bioscience is a global innovator in drug delivery platforms whose lead technology, DehydraTECH, has been shown to increase the bioavailability of APIs
• The company recently announced that Catherine Turkel, PharmD, Ph.D., has joined its board of directors
• Dr. Turkel, who brings over 20 years’ experience, has previously formulated Food and Drug Administration (“FDA”) registration and commercial strategic plans, as well as led global development programs for pharmaceutical and biologic treatments
• Dr. Turkel will lend her drug registration experience and regulatory expertise to Lexaria at a time when the company is journeying toward regulatory approval for DehydraTECH-CBD, its drug candidate for the treatment of hypertension
• Lexaria recently had a pre-IND meeting with the FDA, where it received positive feedback

Companies should bring on board members with strategic growth experience who have “been there, done that,” a June 2022 article in Forbes advises (https://ibn.fm/59n6H). Strategic growth, the article observes, “is one of the most important areas of governance for boards. The more experience on a board, the more efficient you are at developing tried and tested growth strategies… Members with experience down certain paths can guide a company to anticipate and avoid known obstacles, helping to accomplish goals faster.” As Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, charts the long path toward regulatory approval for DehydraTECH(TM)-processed cannabidiol (“CBD”), a prospective treatment for hypertension, the importance of bringing on board members with prior drug registration experience as well as regulatory expertise is not lost on the company. Lexaria recently announced that Catherine Turkel, PharmD, Ph.D., has joined its board of directors (https://ibn.fm/bZbJP). With more than 20 years’ experience, Dr. Turkel has worked as an executive in start-up and mid-size pharma/biotech companies. She founded and was the CEO of Nezee Therapeutics, served as the President and R&D head at Novus Therapeutics – which has been renamed Eledon Pharmaceuticals Inc. (NASDAQ: ELDN) – and currently serves as an independent Board Director at private company Object Pharma and non-profit Prostate Cancer Research. She is also a Dean Advisor at Chapman University School of Pharmacy. Dr. Turkel has formulated Food and Drug Administration (“FDA”) registration and commercial strategic plans and spearheaded global development programs for pharmaceutical and biologic treatments from Phase 1 through Phase 4 across such therapeutic areas as otology, urology, aesthetics, ophthalmology, rare diseases, psychiatry, cardiovascular, neurosciences, and pain. At a previous stint working with Allergan – now a part of AbbVie (NYSE: ABBV) – Dr. Turkel designed and led the pharmaceutical company’s BOTOX(R) Chronic Migraine registration program, leading to revenue of over a billion dollars. “Lexaria is delighted to welcome Dr. Turkel as we continue to position the company for advancement following our recent successful pre-IND (pre-investigational new drug) meeting with the FDA,” commented Lexaria Chair and CEO Chris Bunka. “Catherine’s practical development and regulatory expertise will be of increasing value to Lexaria, and we look forward to working with her.” The onboarding of Dr. Turkel comes on the heels of a Pre-IND meeting regarding Lexaria’s DehydraTECH-CBD for the treatment of hypertension. Reporting that the meeting had yielded positive feedback from the FDA, the company’s August 10 announcement noted that the FDA had seconded its proposal to pursue an abbreviated regulatory pathway that would enable a faster route to commercial approval (https://ibn.fm/s6vqg). In addition, the FDA favorably received the company’s proposed Phase 1b clinical trial protocol that will involve ~100 patients with hypertension with the intention of opening the IND application to allow Lexaria to work toward full registration of its potential treatment. “As a result of the favorable FDA response, Lexaria expects to remain on track to file its full IND application with the FDA by late 2022/ early 2023, as previously announced. This is up to 6-9 months sooner than if the FDA had required modifications in Lexaria’s current IND-enabling work plan, such as performance of additional non-clinical study work,” the August 10 news release reads. Lexaria has shown, through human testing, that DehydraTECH-processed CBD delivers promising results with no serious adverse effects. In 2018, the company administered the substance to 12 participants in a human clinical study (“HCS”) that evidenced 317% more CBD delivered to the blood at 30 minutes than controls. Moreover, three HCSs conducted in 2021, HYPER-H21-1, HYPER-H21-2, and HYPER-H21-3, evidenced rapid and sustained drop in blood pressure, a 23% average drop in overnight blood pressure and reduced arterial stiffness, and attenuated pulmonary artery systolic pressure, respectively (https://ibn.fm/12iYb). For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• While traditional lenders remain reluctant to serve state-licensed cannabis industry prospects, REZYFi focuses on servicing the sector
• ResMac subsidiary expects to accumulate $285 million in retail origination and $250 million in wholesale origination in 2023
• The National Association of Realtors(R) reported one-third of surveyed agents experienced an increase in demand for warehouses, 28% in land demand, and 23% in demand for storefront property

REZYFi, a cannabis mortgage bank servicing the needs of both traditional and non-traditional consumers and businesses, is one of the first mortgage bankers of its kind in the United States, leveraging its position in a market where most traditional lenders remain diffident to serve the state-licensed cannabis industry. Through its two wholly owned subsidiaries – REZYFi Lending and ResMac Inc. – REZYFi is targeting licensed and permitted cannabis companies, owners of real estate who lease to cannabis companies, and companies and individual homeowners seeking a variety of real estate-related first and additional mortgage-based financing and project-specific financing. Through REZYFi Lending, the company is leveraging a wide network to offer multiple options, including 15- to 30-year fixed rate loans, FHA loans, VA loans, reverse mortgages, jumbo loans, and adjustable-rate mortgages. The company expects increased funding in marketing and loan agents to drive significant growth in origination over the next two years, which is supported by the planned launch of a high-margin cannabis division later in 2022. In operation for 13 years, ResMac Inc. has closed more than 20,000 loans for more than 15,000 clients and expects to accumulate $285 million in retail origination and $250 million in wholesale origination in 2023. ResMac is also targeting $600 million in origination through its mortgage correspondent operations during the same period. The company intends to harvest the database of customers within its mortgage servicing operations as an essential source for expanding the new alternative residential loan programs it will operate. In an April 2021 report titled Marijuana and Real Estate: A Budding Issue, the National Association of Realtors(R) (“NAR”) examines the impact that cannabis legalization has on the real estate industry. In states where prescription and recreational cannabis use is legal, more than one-third of the agents surveyed reported an increase in demand for warehouses, 28% observed increases in land demand, and 23% reported increases for storefront property (https://ibn.fm/0C3WE). REZYFi is demonstrating its corporate strengths within the market through experience, a network of independent brokers, and proprietary technology through both subsidiaries. The company is led by a seasoned management team with over 40 years of combined experience in the mortgage and lending industry, as well as experience in the cannabis and hemp marketplace. Over the past five years, REZYFi has developed an extensive network of independent mortgage-related brokers and licensed loan officers – with training that has already commenced for network members to familiarize them with the company’s new service offerings. Through its proprietary automated/machine learning technology, REZYFi shortens loan processing timeframes and increases efficiencies, allowing it to operate its legacy business at staffing levels meaningfully below its competition. For more information, visit the company’s website at www.REZYFi.com. NOTE TO INVESTORS: The latest news and updates relating to REZYFi are available in the company’s newsroom at https://ibn.fm/REZY

• US natural gas prices rose nearly 50% in July, EU benchmark power price hit ten times decade-long average
• Prices expected to remain volatile until at least 2023
• GeoSolar’s SmartGreen(R) systems help building owners achieve energy independence with photovoltaic (“PV”) solar systems and geothermal ground loops
• Additional SmartGreen(R) system customizations include tightening building envelope, insulation upgrades, LED lighting replacement, and EV charging infrastructure
• SEC recently qualified GeoSolar for Regulation A+ capital raise

Energy prices are skyrocketing, especially in Europe where the benchmark power price recently hit 1,000 euros (USD $990) per megawatt-hour – nearly ten times the decade-long average (https://ibn.fm/uXrTc). With no end in sight to the Ukraine conflict, Europeans are bracing for the worst following news that energy prices will remain “high and volatile” until at least 2023 (https://ibn.fm/8hNEF). Accordingly, US natural gas prices rose by nearly 50% in July, dashing any hopes consumers and businesses had for declining inflation (https://ibn.fm/5g4uZ). Some building owners, however, are largely insulated from the crisis by installing GeoSolar Technologies’ SmartGreen(R) residential and commercial energy systems that tap into the power of the sun and earth to dramatically lower or eliminate utility bills. Up to 84 million homes in the United States depend on obsolete fossil fuel-driven energy systems (https://ibn.fm/yQWPy). Not only does that leave homeowners vulnerable to price shocks similar to those seen today, but it also increases dependency on foreign powers, causes geopolitical conflict, and contributes to pollution that compromises the quality of human, animal, and plant life across the planet. GeoSolar is dedicated to advancing technology that addresses all those issues while giving building owners energy independence. The company’s SmartGreen(R) residential and commercial energy systems harness the sun’s power through photovoltaic (“PV”) solar systems that generate electricity year-round to power appliances and charge EVs. In addition, heating and cooling needs are met with geothermal ground loops that use the earth as a heat source or heat sink, depending on the building’s temperature requirements. Solar and geothermal systems are only part of the SmartGreen(R) equation. The system encompasses a total home energy makeover to increase efficiency, including tightening the building envelope, upgrading insulation, replacing windows, and installing LED lights. GeoSolar’s system can be optimized for any building size, type, or design, allowing owners to integrate SmartGreen(R) into new building developments or existing homes within weeks. GeoSolar is dedicated to achieving carbon-free living by 2035. With a successful track record of installations across Colorado, GeoSolar aims to market SmartGreen(R) to over one hundred million homes across the United States with 100% financing options, tax deductions, and utility incentives. The company was recently qualified by the U.S. Securities and Exchange Commission to conduct a Regulation A+ capital raise, and additionally plans to file for an OTCQB listing on the national OTC market with the trading symbol GSOL upon offering completion. For more information on GeoSolar’s Regulation A+ capital raise, please visit https://www.manhattanstreetcapital.com/geosolar-technologies-inc. For more information, visit the company’s website at www.GeoSolarPlus.com. NOTE TO INVESTORS: The latest news and updates relating to GeoSolar Technologies are available in the company’s newsroom at https://ibn.fm/GST

• U.S.-based drug innovator CNS Pharmaceuticals is enrolling patients in a global clinic trial to evaluate the performance of the company’s lead drug candidate, Berubicin, in fighting glioblastomas
• Glioblastoma is an incurable brain cancer that is aggressive in its progression and recurrence, leaving most patients with a life expectancy of less than a year after diagnosis
• CNS’s efforts to fill an unmet medical need arise from promise shown during Berubicin’s initial development by another company over 15 years ago, which included a small-scale human safety trial that produced a patient with no detectable cancer and others that saw tumor shrinkage and stable disease
• The FDA has granted Berubicin Fast Track and Orphan Drug status and enrollment for the current potentially pivotal global Phase 2 clinical trial is taking place in the United States, France, Spain and Switzerland

An incurable brain cancer known as glioblastoma multiforme (“GBM”) has drawn the attention of researchers throughout the world as the medical science industry races to fill an unmet need for an effective treatment. While surgery is a standard procedure for removing cancerous GBM tumors, the tumors tend to regrow within a narrow margin of time because of the cancer’s capacity to infiltrate the surrounding tissues, preventing the surgeon from clearly identifying the boundaries between the tumor and the normal tissue. And because of the vital importance of the brain, overly aggressive tissue removal is out of the question. “So the tumor will come back again, and that sharply decreases the survival rate after treatment,” University of Wisconsin–Madison School of Pharmacy’s Pharmaceutical Sciences Division assistant professor Quanyin Hu stated in a report on the school’s work to develop a GB treatment for improving GBM survival rates in lab animals (https://ibn.fm/CRwdr). Biopharmaceutical innovator CNS Pharmaceuticals (NASDAQ: CNSP) is staking out its own position within the competitive field of research, having already progressed to human trials of the company’s novel GBM solution, known as Berubicin (or WP744). Berubicin is a patented doxorubicin (“Dox”) analog — an anthracycline chemotherapy agent novel in its ability to cross the blood-brain barrier to target tumors directly. Tested against Dox in cancer cells, Berubicin showed a greater capacity to destroy or damage the cancers. In models evaluating intracranial gliomas, Berubicin showed a greater capacity to prolong life than temozolomide, another standard of care in GBM (https://ibn.fm/QdfUa). Other anthracyclines have been limited in their ability to fight brain cancers by their inability to cross the blood-brain barrier, but Berubicin’s unique capacity potentially led to significant outcomes in its earliest safety trial conducted by the drug’s initial developer, Reata Pharmaceuticals. In that small-scale Phase I clinical trial in 2006, one of the two dozen evaluated patients emerged cancer-free and has remained so over the subsequent years up to today. Nearly half of the trial’s other patients experienced a statistically significant improvement in clinical benefit of stable disease or better (https://ibn.fm/mA0KA). For a trial participant patient to survive cancer-free for well over a decade is a remarkable outcome given the disease’s statistics — approximately 13,000 patients receive new GBM diagnosis each year in the United States and have an average survival time of less than a year after diagnosis. Only 10 percent or less survive to five years (https://ibn.fm/H3vyJ). CNS Pharmaceuticals’ ongoing development of Berubicin includes two dozen trial enrollment sites that are already open, with up to 54 planned at selected locations in the United States, Italy, France, Spain and Switzerland, the most recent approvals in Europe being granted in April with additional countries being considered. This global trial is comparing Berubicin responses to yet another GBM standard of care, Lomustine. By next summer, the company expects to have gathered enough data for an interim analysis (https://ibn.fm/l0Jf9). Berubicin has already been granted Fast Track and Orphan Drug designations by the U.S. Food and Drug Administration (“FDA”), which may further boost its development as the company reports its results. For more information, visit the company’s website at www.CNSPharma.com. NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Correlate’s operations have been influenced by the United States’ push to achieve its 2050 carbon goals, along with the evolving ESG criteria which defines the standards by which companies should operate
• With more companies realizing the significance of having and implementing ESG goals, Correlate is looking at an opportunity to grow its customer numbers
• 76% of managers already implement ESG within their fixed income, up from 42% in 2021. Also, 74% of companies incorporate ESG in equities, up from 53% in 2021
• Correlate’s unique value proposition of affordability and potential profit of its ESG-related energy solutions differentiates the company from the rest in the industry, while offering an opportunity for both big and small enterprises to achieve their ESG goals

Correlate Infrastructure Partners (OTCQB: CIPI), a technology-enabled energy optimization and clean energy solutions provider for the United States commercial real estate industry has, since its inception, been committed to delivering a complete suite of proprietary clean energy assessment and fulfilment solutions for the market. This has been largely influenced by recognizing a significant opportunity in the market, coupled with the country’s push to achieve its stated 2050 carbon goals. Correlate’s operations have been further influenced by the evolving environmental, social, and governance (“ESG”) criteria, that define the responsibility standards by which a growing number of companies are being judged in the marketplace. ESG goals have helped to outline corporate policies associated with climate change, relationships with customers, suppliers, and the communities where it operates, along with their leadership and even shareholder rights. Most importantly, they have greatly influenced the push towards renewable sources of energy. As time progresses, more companies are realizing the significance of having and implementing ESG goals, and this is, in turn, presenting a unique opportunity for Correlate to grow its customer numbers. In a recent survey published by Reuters, it was noted that currently 76% of managers actively implement ESG within their fixed income, a significant rise from 42% back in 2021. In addition, the study noted that 74% of companies incorporate ESG in equities, up from 53% in 2021 (https://ibn.fm/jsrEr). This surge, the report noted, reflects managers’ improved ability to assess ESG signals in the asset class, along with investors’ eagerness to diversify beyond ESG equity funds. Companies have even projected that in the next 12 months, 40% of their portfolios will include ESG elements, up 13 percentage points from the 2021 survey. There are several ways through which companies can improve their ESG score. However, the main ones touch on energy efficiency, along with water usage, waste production, and CO2 emissions (https://ibn.fm/20xYq). This is where Correlate comes in. With commercial buildings consuming over 35% of generated electricity in the United States, and emitting too much carbon, there is an increasingly recognized need to shift to more renewable energy sources. With Correlate’s industry-leading energy solution and financing platform, the company is aiding in significantly reducing site-specific energy consumption, deploying clean energy generation and efficiency solutions that help companies achieve their ESG objectives. Already, Correlate has an opportunity pipeline of over $100 million in commercial projects, with over $20 million in awarded backlog. As more companies recognize the value of achieving ESG goals, Correlate can expect to grow its customer numbers and, consequently, its revenue as time progresses. The company’s unique value proposition, including the affordability and profit potential of its ESG-related energy solutions, differentiates Correlate from other players in the industry. It is also lowering the barrier of entry for even small organizations to adopt renewable energy solutions, allowing for the easy achievement of their set ESG goals. This reflects Correlate’s understanding of the market, and its commitment to creating value, not just for its customers but also its shareholders. For company information, visit the company’s website at www.CorrelateInfra.com, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.CorrelateInfra.com/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.CorrelateInfra.com/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

• A 2017 study by McKinsey & Company showed that high performers tend to be 400% more productive than average ones.
• This outlook has shaped Flora Growth’s hiring strategy for 2022, with the appointment of several key individuals whose proven talents and productivity are seen as critical to the company’s goal of delivering the most compelling customer experiences, most recently with the appointment of Elshad Garayev as Flora’s Chief Financial Officer (“CFO”)
• Mr. Garayev’s appointment marks the latest addition to a growing list of leaders ready to elevate the company to another level of international performance

In a study conducted in 2017 by McKinsey & Company, it was established that high performers tend to be 400% more productive than average ones. The study, which involved over 600,000 researchers, athletes, politicians, and entertainers, also revealed that, in a business setting, the gap rises exponentially with a job’s complexity, sometimes by an astounding 800% (https://ibn.fm/SYsVD). The study’s objective was to highlight the importance of hiring the right people for the right job. It was also meant to show why having the right talent on the team can reduce the time it takes to complete tasks and how long it would take to achieve organizational objectives. Most notably, the study noted that for a business strategy involving cross-functional initiatives requiring three years to complete, if 20% of the average talent working became 400% more productive, it would take less than two years to complete. Conversely, if these individuals were 800% more productive, it would take less than one. These dynamics continue to shape the overall hiring approach and process for various organizations in different industries, and Flora Growth (NASDAQ: FLGC) is no exception. Since the beginning of the year, the company has been committed to looking for the best talent in the job market and devising ways to increase their productivity. Its management fully understands that doing so would not only lessen the time taken to achieve its short-term and long-term goals but also significantly cut down on its overall operational costs, thereby creating value for its shareholders. Flora Growth ushered in the new year with the appointment of Tim Leslie as chairman of its newly formed advisory board. It would later bring Derek Pedro, an industry-leading cannabis genetics and cultivation expert, on board as an advisor and named Vessel founder, James Choe as Chief Strategy Officer. In February 2022, Flora Growth announced the appointment of Jessie Casner as the company’s Chief Marketing Officer, and, in March, made two changes to its board. Then, in early June (https://ibn.fm/pxyLZ), Flora announced the appointment of Holly Bell as the new Vice President of Regulatory Affairs in a move that sought to position Flora to make “thoughtful, educated, and bold decisions regarding strategic distribution, cultivation and sales plans.” So far, all of Flora Growth’s appointments have been geared toward strengthening its human resources and moving the company closer to its objectives. Its latest appointment of Elshad Garayev is no different. Mr. Garayev was brought on board to serve as Flora’s Chief Financial Officer (“CFO”) effective on the business day following the date the company will file its mid-year financial results with the Securities and Exchange Commission. “I am very excited to join Flora and to become its Chief Financial Officer,” Garayev noted. “As one of the largest cultivators licensed by the government of Colombia, their robust portfolio of brands and the future of research in the space, Flora presents a truly amazing opportunity to lead the global cannabis supply chain,” he added (https://ibn.fm/5ncEY). Garayev will lend over 25 years of experience in finance, having served in various financial leadership roles in Amazon, Boeing BP, and RPK Capital. He is well versed in supporting successful organizations through developing and implementing accounting and reporting policies and building high-performance finance teams. Mr. Garayev adds to a growing list of competent, experienced, and capable individuals ready to take on the challenges ahead and elevate Flora Growth to another level of performance. These individuals are set to increase the overall productivity of the company’s workforce, allowing Flora to build a design-led collective of plant-based wellness and lifestyle brands that offers the world’s most compelling customer experience. For more information, visit the company’s website at www.FloraGrowth.com. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC